Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica. 2015 Jul;100(7):e272-4. doi: 10.3324/haematol.2015.126557. Epub 2015 Mar 27.
No abstract available

Keywords: clinical trial; heat shock protein; lymphoma; targeted therapy.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Diarrhea / etiology
  • Diarrhea / pathology
  • Drug Administration Schedule
  • Edema / etiology
  • Edema / pathology
  • Fatigue / etiology
  • Fatigue / pathology
  • Female
  • Gene Expression
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • HSP90 Heat-Shock Proteins / genetics
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • Isoxazoles / therapeutic use*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Lymphoma, T-Cell, Peripheral / genetics
  • Lymphoma, T-Cell, Peripheral / mortality
  • Lymphoma, T-Cell, Peripheral / pathology
  • Male
  • Recurrence
  • Remission Induction
  • Resorcinols / therapeutic use*
  • Retrospective Studies
  • Survival Analysis
  • Thrombocytopenia / etiology
  • Thrombocytopenia / pathology
  • Treatment Outcome

Substances

  • 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins
  • Isoxazoles
  • Resorcinols